GR1004168B - ΧΡΗΣΗ ΤΟΥ CIS-ΛΕΥΚΟΧΡΥΣΟΥ ΚΑΙ ΑΛΛΩΝ ΦΑΡΜΑΚΩΝ ή ΓΟΝΙΔΙΩΝ ΚΑΨΥΛΙΩΜΕΝΩΝ ΕΝΤΟΣ ΛΙΠΟΣΩΜΑΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ ΣΤΟΝ ΑΝΘΡΩΠΟ - Google Patents

ΧΡΗΣΗ ΤΟΥ CIS-ΛΕΥΚΟΧΡΥΣΟΥ ΚΑΙ ΑΛΛΩΝ ΦΑΡΜΑΚΩΝ ή ΓΟΝΙΔΙΩΝ ΚΑΨΥΛΙΩΜΕΝΩΝ ΕΝΤΟΣ ΛΙΠΟΣΩΜΑΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ ΣΤΟΝ ΑΝΘΡΩΠΟ

Info

Publication number
GR1004168B
GR1004168B GR20000100384A GR2000100384A GR1004168B GR 1004168 B GR1004168 B GR 1004168B GR 20000100384 A GR20000100384 A GR 20000100384A GR 2000100384 A GR2000100384 A GR 2000100384A GR 1004168 B GR1004168 B GR 1004168B
Authority
GR
Greece
Prior art keywords
cisplatin
liposomes
drugs
treatment
human cancers
Prior art date
Application number
GR20000100384A
Other languages
English (en)
Other versions
GR20000100384A (el
Inventor
Teni Boulikas
Original Assignee
Teni Boulikas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teni Boulikas filed Critical Teni Boulikas
Publication of GR20000100384A publication Critical patent/GR20000100384A/el
Publication of GR1004168B publication Critical patent/GR1004168B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)

Abstract

ποκαλύπτεται μία μέθοδος καψυλιώσεως cis-λευκόχρυσου και άλλων θετικά φορτισμένων φαρμάκων εντός λιποσωμάτων εχόντων διαφορετική σύσταση λιπιδίων στη διπλοστοιβάδα της εσωτερικής και εξωτερικής μεμβράνης. Τα λιποσώματα είναι ικανά να προσεγγίζουν πρωτογενείς όγκους και τις μεταστάσεις τους μετά από ενδοφλέβια έγχυση σε ζώα και ανθρώπους. Ο καψυλιωμένος cis-λευκόχρυσος έχει υψηλή θεραπευτική αποτελεσματικότητα για την εκρίζωση μιας ποικιλίας συμπαγών ανθρώπινων όγκων οι οποίοι περιλαμβάνουν χωρίς περιορισμό το καρκίνωμα του μαστού και το καρκίνωμα του προστάτη. Υποστηρίζεται ότι ο συνδυασμόςτου καψυλιωμένου cis-λευκόχρυσου με καψυλιωμένη δοξορουβικίνη ή άλλα αντινεοπλασματικά φάρμακα έχει θεραπευτική αξία. Υποστηρίζεται επίσης ότι θεραπευτική αξία στην εκρίζωση του καρκίνου έχουν συνδυασμοί καψυλιωμένου cis-λευκόχρυσου με ορισμένα αντικαρκινικά γονίδια τα οποία περιλαμβάνουν χωρίς να περιορίζονται σ' αυτά τα p53, IL-2, IL-12, αγγειοστατίνης και ογκοστατίνης καψυλιωμένα εντός λιποσωμάτων καθώς και συνδυασμοί καψυλιωμένου cis-λευκόχρυσου με HSV-tk και καψυλιωμένη γανκικλοβίρη. ΰ
GR20000100384A 1999-11-05 2000-11-03 ΧΡΗΣΗ ΤΟΥ CIS-ΛΕΥΚΟΧΡΥΣΟΥ ΚΑΙ ΑΛΛΩΝ ΦΑΡΜΑΚΩΝ ή ΓΟΝΙΔΙΩΝ ΚΑΨΥΛΙΩΜΕΝΩΝ ΕΝΤΟΣ ΛΙΠΟΣΩΜΑΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ ΣΤΟΝ ΑΝΘΡΩΠΟ GR1004168B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/434,345 US6511676B1 (en) 1999-11-05 1999-11-05 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes

Publications (2)

Publication Number Publication Date
GR20000100384A GR20000100384A (el) 2001-07-31
GR1004168B true GR1004168B (el) 2003-02-26

Family

ID=23723848

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000100384A GR1004168B (el) 1999-11-05 2000-11-03 ΧΡΗΣΗ ΤΟΥ CIS-ΛΕΥΚΟΧΡΥΣΟΥ ΚΑΙ ΑΛΛΩΝ ΦΑΡΜΑΚΩΝ ή ΓΟΝΙΔΙΩΝ ΚΑΨΥΛΙΩΜΕΝΩΝ ΕΝΤΟΣ ΛΙΠΟΣΩΜΑΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ ΣΤΟΝ ΑΝΘΡΩΠΟ

Country Status (15)

Country Link
US (3) US6511676B1 (el)
EP (1) EP1156789B9 (el)
JP (2) JP2003513911A (el)
CN (1) CN100562311C (el)
AT (1) ATE321541T1 (el)
AU (1) AU777151B2 (el)
CA (1) CA2358948C (el)
CY (1) CY1105628T1 (el)
DE (1) DE60027039T2 (el)
DK (1) DK1156789T3 (el)
ES (1) ES2261251T3 (el)
GR (1) GR1004168B (el)
PT (1) PT1156789E (el)
TW (1) TWI259770B (el)
WO (1) WO2001034130A1 (el)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011986A1 (en) * 1993-10-27 1995-05-04 The Trustees Of Columbia University In The City Of New York METHOD FOR GENERATING A SUBTRACTED cDNA LIBRARY AND USES OF THE GENERATED LIBRARY
US5710137A (en) 1996-08-16 1998-01-20 The Trustees Of Columbia University In The City Of New York Use of a melanoma differentiation associated gene (mda 7) for reversing a cancerous phenotype
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
WO2001037802A1 (en) * 1999-11-29 2001-05-31 Advanced Research And Technology Institute, Inc. Sustained percutaneous delivery of a biologically active substance
US20030072794A1 (en) * 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
AU8466501A (en) * 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
DK1347743T3 (da) * 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Præparat til behandling af inflammatoriske lidelser
US6759058B1 (en) * 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
US8658202B2 (en) * 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6793912B2 (en) * 2001-08-20 2004-09-21 Transave Inc. Treatment of cancers by inhalation of stable platinum-containing formulations
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
JP4778679B2 (ja) * 2001-10-03 2011-09-21 セレーター ファーマシューティカルズ インコーポレイテッド 併用薬剤を送達するための組成物
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
CA2477979A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. An inhalation system for treatment of intracellular infections
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
US20090060992A1 (en) * 2002-05-08 2009-03-05 University Of Central Florida Research Foundation, Inc., Preparation of magneto-vesicles with DOPE/DDAB layers
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
AU2003302314A1 (en) * 2002-08-02 2004-07-09 Transave, Inc. Platinum aggregates and process for producing the same
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
EP1393720A1 (en) * 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
KR101301653B1 (ko) * 2002-10-29 2013-08-30 트랜세이브, 인코포레이티드 항감염제의 지속적인 방출
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
EP1565165A2 (en) * 2002-11-26 2005-08-24 Gilead Sciences, Inc. Liposomal formulations
US7413851B2 (en) * 2002-12-13 2008-08-19 Aurelium Biopharma, Inc. Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7670604B2 (en) 2002-12-13 2010-03-02 Aurelium Biopharma, Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2005062058A1 (en) * 2002-12-13 2005-07-07 Aurelium Biopharma Inc. Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease
CA2512513A1 (en) * 2003-01-03 2004-07-22 Aurelium Biopharma Inc. Hsc70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
US7358042B2 (en) * 2003-03-14 2008-04-15 Aurelium Biopharma, Inc. Triosephosphate isomerase directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
WO2005000266A2 (en) * 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents
CA2535584A1 (en) * 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050153935A1 (en) * 2003-09-12 2005-07-14 Iversen Patrick L. Compound and method for treating androgen-independent prostate cancer
US20050095283A1 (en) * 2003-09-16 2005-05-05 Aphios Corporation Compositions and methods for topically treating diseases
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
ES2411962T3 (es) 2003-10-24 2013-07-09 Gencia Corporation Métodos y composiciones para suministrar polinucleótidos
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
CN100471493C (zh) * 2003-12-17 2009-03-25 梅比欧法姆股份有限公司 含有奥沙利铂的脂质体制剂
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150570A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
CN1976711A (zh) * 2004-03-18 2007-06-06 特兰萨维股份有限公司 通过吸入给药顺铂
EP1746976B1 (en) * 2004-05-03 2017-01-11 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery
CA2566174A1 (en) * 2004-05-21 2005-12-01 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
CN102499981B (zh) 2005-03-03 2016-08-03 雷文斯治疗公司 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法
US20060283742A1 (en) * 2005-06-16 2006-12-21 Canel Lightning Co. Ltd. Multi-lamp display packaging for lamps with collapsible lampshades
US20080088046A1 (en) * 2006-10-13 2008-04-17 Steffen Panzner Amphoteric liposomes, a method of formulating an amphoteric liposome and a method of loading an amphoteric liposome
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
JP5937292B2 (ja) 2005-10-18 2016-06-22 デューク大学 配列特異性およびｄｎａ−結合親和度が変更された、合理設計メガヌクレアーゼ
US20070190180A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
US9107824B2 (en) * 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
US20090304766A1 (en) * 2005-11-30 2009-12-10 Lawrence Mayer Localized delivery of drug combinations
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
CA2838111C (en) 2005-12-08 2016-01-19 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
NZ596471A (en) 2007-01-16 2013-11-29 Musc Found For Res Dev Compositions and methods for diagnosing, treating, and preventing prostate conditions
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
EP2153820A4 (en) 2007-05-14 2013-12-25 Konica Minolta Holdings Inc LIPOSOME AND METHOD FOR PREPARING THE SAME
US20120003294A1 (en) 2007-08-17 2012-01-05 Celator Pharmaceuticals, Inc. Fixed ratio camptothecens/platinum agents
EP2197497B1 (en) 2007-09-27 2016-06-01 ImmunoVaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2209420A4 (en) 2007-10-09 2014-01-22 Univ St Louis IMAGING PARTICLES
US9468607B2 (en) 2007-10-09 2016-10-18 Washington University Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
DK2215223T3 (da) 2007-10-31 2013-07-22 Prec Biosciences Inc Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser
KR100890317B1 (ko) 2008-05-08 2009-03-26 고려대학교 산학협력단 플라티늄 항암제 조성물 및 제제
CN102056622B (zh) * 2008-06-05 2016-04-06 免疫疫苗技术有限公司 包含脂质体、抗原、多核苷酸和含疏水物质的连续相的载体的组合物
WO2009156706A1 (en) * 2008-06-27 2009-12-30 University Of Strathclyde Pulmonary drug delivery with vesicles comprising non-ionic surfactants
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
TWI437001B (zh) * 2009-04-06 2014-05-11 Food Industry Res & Dev Inst 氮雜芬酮（ａｚａｐｈｉｌｏｎｅ）化合物於調節核荷爾蒙受體活性之用途
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
CN102038640B (zh) * 2009-10-26 2013-11-13 石药集团中奇制药技术（石家庄）有限公司 一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
AU2010339809B2 (en) 2009-12-17 2016-05-05 The Washington University Antithrombotic nanoparticle
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
JP2013527157A (ja) 2010-04-15 2013-06-27 ワシントン・ユニバーシティ プロドラッグ組成物、プロドラッグナノ粒子およびその使用方法
PT2611421T (pt) 2010-09-02 2018-11-22 Scripps Research Inst Administração de fármaco dirigida a tumor à base de nanopartículas
PL220281B1 (pl) 2011-09-23 2015-09-30 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA, sposób indukowania odpowiedzi immunologicznej, przeciwciała specyficznie rozpoznające białko hemaglutyniny H5 wirusa grypy i zastosowanie szczepionki DNA
BR112014007927B1 (pt) 2011-10-06 2021-04-13 Immunovaccine Technologies Inc Composições de lipossoma compreendendo um adjuvante e usos das referidas composições e usos das referidas composições
CN102525928B (zh) * 2012-02-20 2014-04-02 中国药科大学 一种顺铂长循环脂质体及其制备方法
KR102277921B1 (ko) 2012-05-21 2021-07-14 인스메드 인코포레이티드 폐 감염을 치료하기 위한 시스템
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2012387679A1 (en) * 2012-08-13 2014-10-23 Regulon, Inc. Methods for treatment of cancer using Lipoplatin
JP2015530387A (ja) 2012-09-04 2015-10-15 エライゾン ファーマシューティカルズ， エルエルシー 脂質複合体化シスプラチンによる肺癌の再発防止
PT2897620T (pt) 2012-09-21 2020-09-03 Intensity Therapeutics Inc Método de tratamento de cancro
WO2014052634A1 (en) * 2012-09-27 2014-04-03 The University Of North Carolina At Chapel Hill Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof
US10113151B2 (en) 2012-10-29 2018-10-30 The Regents Of The University Of California Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
EP3581186A1 (en) 2012-11-29 2019-12-18 Insmed Incorporated Stabilized vancomycin formulations
EP4374924A2 (en) 2013-10-18 2024-05-29 Novartis AG Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
PL3142643T3 (pl) 2014-05-15 2019-12-31 Insmed Incorporated Sposoby leczenia zakażeń płuc prątkami niegruźliczymi
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
AU2016310476B8 (en) 2015-08-21 2021-10-07 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
JP6924431B2 (ja) * 2015-10-13 2021-08-25 株式会社ケーナインラボ ヒトを除く哺乳動物への薬剤の投与方法
MA42991A (fr) 2015-10-16 2018-08-22 Ipsen Biopharm Ltd Stabilisation de compositions pharmaceutiques de camptothécine
FI127460B (en) 2016-01-15 2018-06-29 Targovax Oy COMBINATION OF ADENOVIRUS AND CHEMOTHERAPY AGENTS FOR CANCER CARE
WO2017192290A1 (en) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs
FR3051674B1 (fr) * 2016-05-31 2019-11-08 Universite De Bourgogne Lipoproteines chargees en complexes de platine pour le traitement du cancer
JP2019533684A (ja) 2016-11-02 2019-11-21 イプセン バイオファーム リミティド リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置
WO2019094648A1 (en) * 2017-11-08 2019-05-16 L.E.A.F. Holdings Group Llc Platinum complexes and uses thereof
CN108042490B (zh) * 2018-01-10 2020-09-15 华中科技大学 纳米载药系统、其制备方法、药物组合物及在治疗癌症中的应用
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
JP7197106B2 (ja) * 2018-04-27 2022-12-27 国立大学法人北海道大学 脂質ナノ粒子
US11246945B2 (en) 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2862498A (en) * 1957-06-14 1958-12-02 Don J Weekes Endotracheal tube
US3554673A (en) * 1969-01-31 1971-01-12 Sage Instr Inc Syringe pump
US3683908A (en) * 1969-10-20 1972-08-15 Tantrimudalige Anthony Don Mic Apparatus for sealing the oesophagus and providing artificial respiration
US4104357A (en) * 1973-01-10 1978-08-01 Monster Molding, Inc. Method of rotational molding about plural axes at low rotational speeds
US3931822A (en) * 1974-02-26 1976-01-13 Marici Frank N Automatic alternating cuff endo tracheal tube inflator
US4231365A (en) * 1978-01-30 1980-11-04 Scarberry Eugene N Emergency resuscitation apparatus
DE2816203C2 (de) * 1978-04-14 1982-07-15 Dr.Ing.H.C. F. Porsche Ag, 7000 Stuttgart Schalteinrichtung für ein elektrisch gesteuertes Brennstoff-Einspritzsystem bei Brennkraftmaschinen
GB2111394B (en) * 1981-12-16 1985-09-11 Archibald Ian Jeremy Brain Artificial airway device
US4553540A (en) * 1983-08-16 1985-11-19 Straith Richard E Airway
US4793327A (en) * 1986-01-21 1988-12-27 Frankel Alfred R Device for opening a patient's airway during automatic intubation of the trachea
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US4832020A (en) * 1987-03-24 1989-05-23 Augustine Scott D Tracheal intubation guide
US5203320A (en) * 1987-03-24 1993-04-20 Augustine Medical, Inc. Tracheal intubation guide
US5042469A (en) * 1987-03-24 1991-08-27 Augustine Medical, Inc. Tracheal intubation guide
US4872483A (en) * 1987-12-31 1989-10-10 International Medical Products, Inc. Conveniently hand held self-contained electronic manometer and pressure modulating device
US4953547A (en) * 1989-01-26 1990-09-04 Poole Jr Samuel E Drug administering endotracheal respiration systems
GB2229367A (en) * 1989-03-22 1990-09-26 Archibald Ian Jeremy Brain Artificial airway device
WO1990011780A1 (en) * 1989-03-31 1990-10-18 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5174283A (en) * 1989-11-08 1992-12-29 Parker Jeffrey D Blind orolaryngeal and oroesophageal guiding and aiming device
US5038766A (en) * 1989-11-08 1991-08-13 Parker Jeffrey D Blind orolaryngeal and oroesophageal guiding and aiming device
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
GB9102821D0 (en) * 1991-02-11 1991-03-27 Brain Archibald Ian Jeremy An intubating laryngeal mask airway
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5339808A (en) * 1991-04-02 1994-08-23 Don Michael T Anthony Endotracheal-esophageal intubation devices
US5235973A (en) * 1991-05-15 1993-08-17 Gary Levinson Tracheal tube cuff inflation control and monitoring system
GB9119703D0 (en) * 1991-09-14 1991-10-30 Dingley John Medico-surgical device
MX9301163A (es) * 1992-03-05 1994-07-29 Brain Archibald Ian Jeremy Mascara laringea y metodo para su fabricacion.
GB9204754D0 (en) * 1992-03-05 1992-04-15 Brain Archibald Ian Jeremy Mould for manufacture of a laryngeal mask
US5249571A (en) * 1992-05-21 1993-10-05 Brain Archibald Ian Jeremy Laryngeal clamp airway
US5297547A (en) * 1992-07-30 1994-03-29 Brain Archibald Ian Jeremy Laryngeal mask construction
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5355879A (en) * 1992-09-28 1994-10-18 Brain Archibald Ian Jeremy Laryngeal-mask construction
US5443063A (en) * 1993-08-31 1995-08-22 The Johns Hopkins University Cuffed oro-pharyngeal airway
US5599301A (en) * 1993-11-22 1997-02-04 Advanced Cardiovascular Systems, Inc. Motor control system for an automatic catheter inflation system
GB2285765B (en) * 1994-01-12 1997-10-29 Archibald Ian Jeremy Brain Forming tool for use with a laryngeal mask
US5529582A (en) * 1994-02-01 1996-06-25 Fukuhara; Tomio Apparatus for inserting laryngeal mask
US5582167A (en) * 1994-03-02 1996-12-10 Thomas Jefferson University Methods and apparatus for reducing tracheal infection using subglottic irrigation, drainage and servoregulation of endotracheal tube cuff pressure
JP3782123B2 (ja) * 1994-05-31 2006-06-07 住友ベークライト株式会社 咽腔用エアウエイ
US5569219A (en) * 1994-09-13 1996-10-29 Hakki; A-Hamid Collapsible catheter
GB9422224D0 (en) * 1994-11-03 1994-12-21 Brain Archibald Ian Jeremy A laryngeal mask airway device modified to detect and/or stimulate mescle or nerve activity
US5477851A (en) * 1995-01-26 1995-12-26 Callaghan; Eric B. Laryngeal mask assembly and method for removing same
GB9504657D0 (en) * 1995-03-08 1995-04-26 Neil Michael J O An improved artificial airway device
GB9505134D0 (en) * 1995-03-14 1995-05-03 Smiths Industries Plc Laryngeal mask airways
GB9505399D0 (en) * 1995-03-17 1995-05-03 Smiths Industries Plc Medico-surgical devices
US5908777A (en) 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
GB9513860D0 (en) * 1995-07-07 1995-09-06 Smiths Industries Plc Securing devices
MY115052A (en) * 1995-10-03 2003-03-31 Archibald Ian Jeremy Brain Laryngeal mask airway incorporating an epiglottic elevating mechanism
US5791341A (en) * 1995-12-19 1998-08-11 Bullard; James Roger Oropharyngeal stent with laryngeal aditus shield and nasal airway with laryngeal aditus shield
US5694929A (en) * 1996-02-26 1997-12-09 Christopher; Kent L. Method and apparatus for ventilation/oxygenation during guided insertion of an endotracheal tube
US5623921A (en) * 1996-04-10 1997-04-29 Kinsinger; J. William Laryngeal mask airway and method for its use
US5894060A (en) 1996-06-28 1999-04-13 Boulikas; Teni Cloning method for trapping human origins of replication
US5682880A (en) * 1996-07-26 1997-11-04 Brain; Archibald Ian Jeremy Laryngeal-mask airway with guide element, stiffener, and fiberoptic access
DK0929293T3 (da) 1996-08-23 2004-02-02 Sequus Pharm Inc Liposomer indeholdende en cisplatinforbindelse
US5738094A (en) * 1996-08-30 1998-04-14 Hoftman; Moshe Anesthesia/respirator mask with reduced nasal section enclosure and inflatable cuff
GB9619432D0 (en) * 1996-09-18 1996-10-30 Smiths Industries Plc Laryngeal mask assemblies
GB2318297B (en) * 1996-10-16 2000-04-12 Smiths Industries Plc A tracheal shield assembly
GB9622880D0 (en) * 1996-11-02 1997-01-08 Smiths Industries Plc Laryngeal mask airways and thier manufacture
GB9624029D0 (en) * 1996-11-19 1997-01-08 Smiths Industries Ltd Laryngeal mask airways and their manufacture
US5843475A (en) * 1996-12-06 1998-12-01 Board Of Regents, The University Of Texas System Delivery and activation through liposome incorporation of diaminocyclohexane platinum (II) complexes
GB9702337D0 (en) * 1997-02-05 1997-03-26 Smiths Industries Plc Laryngeal mask airways and their manufacture
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
GB9705586D0 (en) * 1997-03-18 1997-05-07 Smiths Industries Plc Laryngeal mask assemblies
GB9705585D0 (en) * 1997-03-18 1997-05-07 Smiths Industries Plc Laryngeal mask assemlies
GB9705537D0 (en) * 1997-03-18 1997-05-07 Smiths Industries Plc Laryngeal mask assemblies
US5743254A (en) * 1997-03-18 1998-04-28 Parker Medical Limited Partnership Orotracheal intubation guide
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US5937860A (en) * 1997-04-10 1999-08-17 Cook; Daniel J. Laryngeal mask
GB9708568D0 (en) * 1997-04-29 1997-06-18 Smiths Industries Ltd Cuffed medico-surgical tubes
US5988167A (en) * 1997-05-02 1999-11-23 Kamen; Jack M. Foam cuff for laryngeal mask airway
US5850832A (en) * 1997-06-23 1998-12-22 Chu; Kyo Y. Laryngeal mask airway insertion guide
GB9721840D0 (en) * 1997-10-16 1997-12-17 Smiths Industries Plc Laryngeal mask assemblies
US6003510A (en) * 1997-12-04 1999-12-21 Anunta; Boonchuay Hand tool for introducing a laryngeal mask
GB9817537D0 (en) * 1998-08-13 1998-10-07 Brain Archibald Ian Jeremy A laryngear mask airway with mutually independant laterally-placed ultra-flexible eastric access/discharge and airway tubes
US6705318B1 (en) * 1999-04-09 2004-03-16 Archibald I. J. Brain Disposable LMA
US6390093B1 (en) * 1999-04-14 2002-05-21 Vital Signs, Inc. Artificial airway device and method of its use
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US6427688B1 (en) * 2000-02-01 2002-08-06 Dura Pharmaceuticals, Icn. Dry powder inhaler
GB2383755B (en) * 2002-01-04 2004-02-25 Future Top Medical Environment Obturator for use with a laryngeal mask airway

Also Published As

Publication number Publication date
WO2001034130A9 (en) 2001-12-06
AU777151B2 (en) 2004-10-07
US6511676B1 (en) 2003-01-28
US7393478B2 (en) 2008-07-01
DE60027039T2 (de) 2007-04-12
DE60027039D1 (de) 2006-05-18
JP2003513911A (ja) 2003-04-15
US20090280164A1 (en) 2009-11-12
EP1156789B9 (en) 2006-06-28
EP1156789A1 (en) 2001-11-28
WO2001034130A1 (en) 2001-05-17
DK1156789T3 (da) 2006-08-07
AU1104801A (en) 2001-06-06
JP2012041364A (ja) 2012-03-01
CY1105628T1 (el) 2010-12-22
ES2261251T3 (es) 2006-11-16
CA2358948A1 (en) 2001-05-17
EP1156789A4 (en) 2002-08-07
US20030185879A1 (en) 2003-10-02
EP1156789B1 (en) 2006-03-29
ATE321541T1 (de) 2006-04-15
GR20000100384A (el) 2001-07-31
CA2358948C (en) 2010-01-05
CN100562311C (zh) 2009-11-25
CN1343118A (zh) 2002-04-03
PT1156789E (pt) 2006-08-31
TWI259770B (en) 2006-08-11
JP5711099B2 (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
GR1004168B (el) ΧΡΗΣΗ ΤΟΥ CIS-ΛΕΥΚΟΧΡΥΣΟΥ ΚΑΙ ΑΛΛΩΝ ΦΑΡΜΑΚΩΝ ή ΓΟΝΙΔΙΩΝ ΚΑΨΥΛΙΩΜΕΝΩΝ ΕΝΤΟΣ ΛΙΠΟΣΩΜΑΤΩΝ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ ΣΤΟΝ ΑΝΘΡΩΠΟ
US5395400A (en) Heated headgear
EP1476034A4 (en) VERSATILE CLOTHING
WO1998012618A3 (en) Wearable electronics packaging
GB2333223B (en) Body protection garment incorporating buoyancy means
AU6432000A (en) Breathable garment to be worn to improve the comfort of the human body
USD453055S1 (en) Cooling vest
EP3590371A1 (en) Attire for facilitating the use of stones for chakras
USD403841S (en) Illuminated headband
US20150245679A1 (en) Perspiration Shield
EP0980653A3 (de) Schutzanzug
USD469604S1 (en) Truncated deep bandolier
USD457273S1 (en) Safety vest
KR102623606B1 (ko) 다기능 온열수단
CN210642556U (zh) 一种新型防护户外棉服
CN208510115U (zh) 一种雨衣头盔
CN213045251U (zh) 一种带有反光标识的风衣
CA2276501A1 (en) Elbow brace with movable support
CN207285270U (zh) 一种防毒蛇咬伤的护腿和护臂装具
CN2166620Y (zh) 可保护人身安全的防刺衣
CN2311153Y (zh) 新型肘、膝保护套
KR200221252Y1 (ko) 목 보호대가 체결된 방탄헬멧
CN2251889Y (zh) 自热保健马甲
GB2362311A (en) Padded horse riding coat
DE59804228D1 (de) Unterziehschutzweste mit multiaxialem Trägersystem

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees

Effective date: 20160602